SCHEMBL5538271

SCHEMBL5538271

COC(=O)c1ccccc1CCO[C]=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
LMNA P02545 2/20 0.60
TSHR P16473 2/20 0.46
HSD17B10 Q99714 3/20 0.45
CFTR P13569 1/20 0.45
HIF1A Q16665 1/20 0.45
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 4/20 0.44
POLB P06746 2/20 0.44
ATM Q13315 1/20 0.44
GLA P06280 1/20 0.42
HTT P42858 2/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536082 0.85 TSHR (0.57) ALDH1A1LMNATSHRHSD17B10KMT2A
SCHEMBL712323 0.84 ALDH1A1 (0.55) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL16445957 0.83 ALDH1A1 (0.68) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL10360804 0.83 ALDH1A1 (0.77) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL21958091 0.79 ALDH1A1 (0.62) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL29875722 0.78 ALDH1A1 (0.70) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL2655484 0.78 ALDH1A1 (0.70) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL6941818 0.78 ALDH1A1 (0.70) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL1629682 0.78 ALDH1A1 (0.70) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL5538272 0.78 ALDH1A1 (0.60) ALDH1A1LMNATSHRHSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885LMNA 4152/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.